Datamonitor Healthcare: data analysis and insight, Scrip: in...
The tumor-agnostic developer’s toolkit
New product launches and label expansions will drive growth despite genericization of key brands
What’s the overall outlook for the multiple myeloma (MM) market? Positive or negative?
The answer is positive! Datamonitor Healthcare predicts that the extended indications for key MM drugs will lead to considerable uptake across the treatment algorithm, which will strongly contribute to the total sales of the overall MM market.
Biomedtracker: see the drug development process through anal...
Anticipate the biggest, most impactful expected catalysts of early 2020 with the guidance and insights from Pharma Intelligence. Building off Biomedtracker’s Early 2020 Outlook report, our live webinar will include market context for these upcoming milestones and additional insights from Datamonitor Healthcare’s Therapeutic Area Directors.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: